KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Operating Expenses (2016 - 2025)

Nektar Therapeutics has reported Operating Expenses over the past 16 years, most recently at $49.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $49.5 million for Q4 2025, down 71.3% from a year ago — trailing twelve months through Dec 2025 was $101.5 million (down 50.15% YoY), and the annual figure for FY2025 was $195.3 million, down 4.07%.
  • Operating Expenses for Q4 2025 was $49.5 million at Nektar Therapeutics, up from $43.5 million in the prior quarter.
  • Over the last five years, Operating Expenses for NKTR hit a ceiling of $174.4 million in Q2 2022 and a floor of $4.1 million in Q2 2025.
  • Median Operating Expenses over the past 5 years was $72.8 million (2022), compared with a mean of $83.8 million.
  • Biggest five-year swings in Operating Expenses: tumbled 95.51% in 2024 and later surged 708.29% in 2025.
  • Nektar Therapeutics' Operating Expenses stood at $137.9 million in 2021, then crashed by 45.99% to $74.5 million in 2022, then fell by 22.95% to $57.4 million in 2023, then skyrocketed by 200.35% to $172.4 million in 2024, then tumbled by 71.3% to $49.5 million in 2025.
  • The last three reported values for Operating Expenses were $49.5 million (Q4 2025), $43.5 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.